|Publication number||USRE33239 E|
|Application number||US 07/350,891|
|Publication date||Jun 26, 1990|
|Filing date||May 12, 1989|
|Priority date||Sep 6, 1983|
|Publication number||07350891, 350891, US RE33239 E, US RE33239E, US-E-RE33239, USRE33239 E, USRE33239E|
|Original Assignee||Farmaceutisk Laboratorium Ferring A/S|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (21), Non-Patent Citations (19), Referenced by (20), Classifications (13), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation of application Ser. No. 529,769, filed Sept. 6, 1983, now abandoned.
1. Field of the Invention
This invention concerns an enema solution or suspension which is suitable for rectal administration of 5-.[.aminosalicyclic.]..Iadd.aminosalicylic .Iaddend.acid (5-ASA) in mammals. The present enema solutions are useful in the treatment of bowel diseases, in particular, ulcerative colitis, Crohn's disease located in the colon and .[.proctoigmoiditis.]. .Iadd.proctosigmoiditis.Iaddend..
2. State of the Prior Art
.[.Salicyclazosulfapyridine.]. .Iadd.Salicylazosulfapyridine .Iaddend.(SASP) has for a long period of time been a cornerstone in the treatment of ulcerative colitis and has been used in various pharmaceutical dosage forms including enemas. When SASP reaches the colon, it is split by bacteria into sulfapyridine (SP) and 5-ASA and, as explained in detail in copending U.S. application Ser. No. 555,533, filed Nov. 28, 1983, which is a continuation application of Ser. No. 270,517, filed May 29, 1981, now abandoned, and based on International Application No. WO81/02671, both of which are incorporated by reference, most experts now hold the active moiety of SASP to be 5-ASA.
Azad Khan et al, Lancet, 1977, pp. 892-95, compared suspensions of SASP, SP and 5-ASA administered rectally and concluded that the therapeutic active moiety was 5-ASA and that SP only acts as a carrier to ensure that 5-ASA is not released until it has reached the colon. Stability tests showed that SASP and SP suspensions were stable at room temperature while the 5-ASA suspension showed some decay and had to be made up in fresh batches every three months and stored in a refrigerator until used.
Similar observations were made by Campieri et al, Lancet, Aug. 8, 1981, pp. 220-21, who carried out a comparison trial between 5-ASA and hydrocortisone. Since 5-ASA turned brown in solution, they added charcoal to the hydrocortisone as coloring agent in order to ensure double-blindness.
While enemas containing 5-ASA have thus proved useful in the treatment of ulcerative colitis, their limited stability is a major problem and a solution to this problem would be of great advantage.
It has now been discovered that the desired stability can be obtained by packaging an aqueous solution or suspension of 5-ASA or a pharmaceutically acceptable salt or ester thereof being contained in a plastic bottle under an inert gas in a diffusion-tight package impervious to light in the same inert gas as was used in the plastic bottle.
The 5-ASA solution or suspension should further contain a chelating agent, an antioxidant and a buffer in order to provide a pH value of from 4 to 7.
The presence of the same inert gas on both sides of the plastic bottle provides an equilibrium which effectively cooperates with the various stabilizers and the diffusion-tight light-impervious package and provides a stability of a year or more.
Hence, the invention concerns a packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, an antioxidant and a buffer, said solution or suspension having a pH value of from 4 to 7 and being contained in a plastic bottle under an inert gas, said plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.
The invention will be further illustrated with reference to the accompanying single FIGURE of drawing which shows a partly torn away package containing a liquid-filled enema bottle.
The drawing shows a laminated foil package 1 enclosing an anema bottle 2 containing an enema solution or suspension 3.
The laminated foil package 1 is heat-sealed along each edge at 1a and along the bottom at 1b and the top at 1c, respectively.
Preferably, the package is formed from a heat-sealable plastic-metal laminate, e.g., a polyethylenealuminum laminate 4.
The bottle is constituted by a container part 6, an intermediate part 7 and a sealed closure part 8.
The therapeutically active ingredient 5-ASA may be present in the form of the free acid or a pharmaceutically acceptable salt or ester thereof.
The salts of 5-ASA may be acid addition salts, in particular, the hydrochloride, but any pharmaceutically acceptable, non-toxic organic or inorganic acid may be used.
Also, salts formed with the carboxylic acid group may be used. As examples may be mentioned alkali metal salts (K, Na), alkaline earth metal salts (Ca, Mg), but again any pharmaceutically acceptable, non-toxic salt may be used. The Na- and Ca- salts are preferred.
In German Offenlegungsschrift No. 2,712,934, a number of esters of ortho-, meta- and .[.para-salicyclic.]. .Iadd.para-salicylic .Iaddend.acid are disclosed. Said esters are effective as ultraviolet ray screening compounds thereby rendering themselves useful in preventing solar burning. The disclosed meta- (or 5-).[.aminosalicyclic.]..Iadd.aminosalicylic .Iaddend.esters and a number of related esters are also applicable in the enema according to the invention.
Applicable esters are, e.g., straight chain or branched C1 -C18 alkyl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, myristyl, cetyl, and stearyl, etc.; straight chain or branched C2 -C18 alkenyl esters, e.g., vinyl, allyl, undecenyl, oleyl, linolenyl, etc.; C3 -C8 cycloalkyl esters, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, etc.; aryl esters, e.g., phenyl, toluyl, xylyl, naphthyl, etc.; alicyclic esters, e.g., menthyl, etc.; or aralkyl esters, e.g., benzyl, phenethyl, etc.
Generaly speaking, the proper selection of the active ingredient depends on the selected type of formulation, the disease pattern, especially the site and type of the disease, and the desired release of the active ingredient, as shall be further expounded below together with the concept "effective amount".
The physical state and solubility characteristics of the 5-ASA derivatives must be taken into account when selecting a suitable carrier composition for the ingredient.
The preferred active ingredient at present is the free acid, 5-ASA.
Preferably, the 5-ASA is extremely pure in order to prevent autooxidation. The purity is manifested by the absence of additional high pressure liquid chromatography (HPLC) peaks (both determined fluospectrophotometrically and spectrophotometrically in general).
The effective amount of the 5-ASA or ester or salt thereof contained in the enema depends upon the extent of the disease and for adults generally in amounts of from 0.2 to 4 g 5-ASA per 100 ml enema will be used. Whether or not the enema- is a suspension or solution i.a. depends on the amount of 5-ASA and the pH. The solubility of 5-ASA in water is about 2 g/100 ml at pH 7, but only about 0.2 g/100 ml at pH 4.8.
By administering an enema suspension, which might be provided at the more acidic pH values in the range from 4 to 7, a kind of slow-release of the 5-ASA might be obtained.
Since 5-ASA is assumed to be topically effective at the ulcer sites in case of colitis such slow release is believed to be the most beneficial to the patient.
The enema solution or suspension also contains a chelating agent to avoid autooxidation catalyzed by metal ions which may be present even in analytic grade chemicals. Any of the classic chelating agents may be used, but the preferred chelating agents are polymethylene diaminetetraacetic acid, in particular, ethylene diaminetetraacetic acid (EDTA) and its alkali metal salts. The preferred amount of chelating agent is from 5 to 30 mg/100 ml solution or suspension, preferably about 20 mg/100 ml.
Further, the solution or suspension contains an antioxidant to prevent oxidation of the 5-ASA. Preferred antioxidants are sodium or potassium pyrosulfite, but other well-known antioxidants might be used, e.g., ascorbic acid. The preferred amount is 50-200 mg/100 ml suspension or solution, preferably about 100 mg/100 ml.
Further, the enema solution contains a suitable buffer in order to maintain the desired pH value in the range of from 4 to 7. The preferred pH is from 4.5 to 5, in particular, about 4.8. This pH is advantageously established by means of a citric acid buffer since citric, acid has a pka of 4.77.
Other applicable buffers are bicarbonate buffers if a pH of 6 to 7 is desired since the pka for bicarbonate is 6.5.
Generally speaking, any buffer system might be used which provides the proper pH and does not interfere with the other components of enema.
The gas used in the bottle and the package should be inert with relation to the solution or suspension. Preferred inert gases are nitrogen or argon, but also carbon dioxide may be used if the solution or suspension contains a bicarbonate buffer.
The plastic bottle is preferably made by blow forming from a polyethylene granulate which has been deoxidized by alternating vacuum and nitrogen treatments.
The diffusion-tight light-impervious package material is preferably made from a heat-sealable plastic-metal laminate, e.g., plastic-aluminum laminate, where any heat-sealable plastic material, e.g., polyethylene, might be used.
A packaged suspension according to the invention may be prepared as follows:
______________________________________5-ASA* 1 g/100 mlEDTA 20 mgSodium pyrosulfite 0.2 gCitric acid 1 gSodium hydroxide q.s. (up to pH = 4.8 about 0.35 g)Sterile water up to 100 ml______________________________________ *5-ASA is extremely pure to avoid autooxidiation no additional HPLC peak (both fluospectrophotometrically and spectrophometrically in general).
The suspension is prepared and dispensed in an inert gas, e.g., nitrogen or argon.
The polyethylene granulate is deoxidized by alternating vacuum and nitrogen treatments. The deoxidized granulate is extruded, formed by blowing and the 5-ASA suspension is filled into a plastic bottle blower/packing machine. The inert gas used for dispensing also constitutes the supporting air, blowing air and the air in the chamber in which the filling and forming procedures are taking place.
The bottle is conveyed directly to a packing chamber containing the same inert gas in which the bottles are packed in aroma-tight, light-impervious (plastics aluminum laminate) bags which are sealed by welding before they drop into the atmosphere.
Enema suspensions contain 1 g and 2 g 5-ASA per 100 ml prepared in analogy with the above procedure have been tested for stability by fluospectrophotometry and HPLC.
After storage at room temperature for more than a year, no significant change was observed neither with regard to color or 5-ASA content.
It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2647853 *||Nov 28, 1950||Aug 4, 1953||Lab Francais Chimiotherapie||Injectable solution of salt of para-aminosalicylic acid|
|US2658073 *||Mar 18, 1950||Nov 3, 1953||Monsanto Chemicals||Purification of para-aminosalicylic acid and its alkali metal salts|
|US2844625 *||Sep 13, 1954||Jul 22, 1958||Miles Lab||p-aminosalicylic acid|
|US2939818 *||Apr 9, 1957||Jun 7, 1960||Pfizer & Co C||Aqueous therapeutic compositions|
|US3044118 *||Jun 23, 1958||Jul 17, 1962||Du Pont||Molding method and apparatus|
|US3230143 *||May 14, 1965||Jan 18, 1966||Merck & Co Inc||Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine|
|US3621892 *||Sep 4, 1969||Nov 23, 1971||Gillespie Thomas J||Resin vacuum degassing and dispensing system and method|
|US3777019 *||Feb 3, 1971||Dec 4, 1973||American Home Prod||Stabilized chlorpromazine hydrochlo-ride solution for use in disposable cartridges|
|US3937778 *||Oct 24, 1974||Feb 10, 1976||Toshiba Kikai Kabushiki Kaisha||Method of vacuum-pressure injection moulding|
|US4071620 *||Jan 10, 1977||Jan 31, 1978||American Home Products Corporation||Stabilization of oxygen sensitive dose forms|
|US4150744 *||Nov 23, 1977||Apr 24, 1979||Smith & Nephew Pharmaceuticals Ltd.||Packaging|
|US4340550 *||Nov 24, 1980||Jul 20, 1982||E. I. Du Pont De Nemours And Company||Oligomer pellets of ethylene terephthalate|
|US4406888 *||Jan 9, 1981||Sep 27, 1983||Pfizer Inc.||Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution|
|US4440763 *||Mar 18, 1981||Apr 3, 1984||Block Drug Company, Inc.||Use of 4-aminosalicyclic acid as an anti-inflammatory agent|
|US4447373 *||Feb 16, 1982||May 8, 1984||The Procter & Gamble Company||Process for making filled articles from polymeric material|
|US4657900 *||Mar 28, 1985||Apr 14, 1987||Rowell Laboratories||Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method|
|DD150694A1 *||Title not available|
|DE2712934A1 *||Mar 24, 1977||Oct 5, 1978||Mundipharma Ag||Mittel, insbesondere gegen hautschaeden durch ultraviolette strahlung, sowie verfahren zu seiner herstellung|
|DK120280B||Title not available|
|WO1981002671A1 *||Mar 20, 1981||Oct 1, 1981||Ferring Farma Lab||Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration|
|WO1981002672A1 *||Mar 20, 1981||Oct 1, 1981||Ferring Farma Lab||Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease|
|1||Allgayer, H. et al., "Determination of the pK Values of 5-Aminosalicyclic Acid and N-Acetylaminosalicylic Acid and Comparison of the pH Dependent Lipuid-Water Partition Coefficients of Sulphasalazine and its Metabolites", Arzneim, Forsch. 35(II), No. 9 (1985), pp. 1457-1459.|
|2||*||Allgayer, H. et al., Determination of the pK Values of 5 Aminosalicyclic Acid and N Acetylaminosalicylic Acid and Comparison of the pH Dependent Lipuid Water Partition Coefficients of Sulphasalazine and its Metabolites , Arzneim, Forsch. 35(II), No. 9 (1985), pp. 1457 1459.|
|3||*||Angren, A., J. Pharm. Pharmac, vol. 7, p. 549.|
|4||Binder, V. et al., "Topical 5-Aminosalicyclic Acid Versus Prednisolone in Ulcerative Proctosigmoiditis", Digestive Diseases & Sciences, Oct. 3, 1985.|
|5||*||Binder, V. et al., Topical 5 Aminosalicyclic Acid Versus Prednisolone in Ulcerative Proctosigmoiditis , Digestive Diseases & Sciences, Oct. 3, 1985.|
|6||Bondesen, S. et al., "5-Aminosalicyclic Acid Enemas in Patients with Active Ulcerative Colitis", Scand. J. Gasterenterol 19:677-687 (1984).|
|7||*||Bondesen, S. et al., 5 Aminosalicyclic Acid Enemas in Patients with Active Ulcerative Colitis , Scand. J. Gasterenterol 19:677 687 (1984).|
|8||Campieri, M. et al., "Treatment of Ulcerative Colitis with High-Dose 5-Aminosalicyclic Acid Enemas", LANCET, Aug. 8, 1981, pp. 270-271.|
|9||*||Campieri, M. et al., Treatment of Ulcerative Colitis with High Dose 5 Aminosalicyclic Acid Enemas , LANCET, Aug. 8, 1981, pp. 270 271.|
|10||Hvidberg, S. et al., "The Fate of 5-Amino-Salicyclic After Rectal Instillation in Patients with Active Procto-Sigmoiditis", CPT 83 Abstract.|
|11||*||Hvidberg, S. et al., The Fate of 5 Amino Salicyclic After Rectal Instillation in Patients with Active Procto Sigmoiditis , CPT 83 Abstract.|
|12||Khan, A. K. et al., "An Experiment to Determine the Active Therapeutic Moiety of Sulphasalazine", LANCET, Oct. 29, 1977, pp. 892-895.|
|13||*||Khan, A. K. et al., An Experiment to Determine the Active Therapeutic Moiety of Sulphasalazine , LANCET, Oct. 29, 1977, pp. 892 895.|
|14||*||Martindale, the Extra Pharmacopoeia, 28th Edition, the Pharmaceutical Press, 1982, 6673 e, Sodium Metabisulphite, pp. 1291 1292.|
|15||Martindale, the Extra Pharmacopoeia, 28th Edition, the Pharmaceutical Press, 1982, 6673-e, Sodium Metabisulphite, pp. 1291-1292.|
|16||Rhodes, J. M., "Medical Treatment of Ulcerative Colitis and Crohn's Disease", Journal of Clinical and Hospital Pharmacy (1983, 8, 219-232).|
|17||*||Rhodes, J. M., Medical Treatment of Ulcerative Colitis and Crohn s Disease , Journal of Clinical and Hospital Pharmacy (1983, 8, 219 232).|
|18||Willoughby, C. et al, "5-Aminosalicyclic Acid (Pentasa) in Enema Form for the Treatment of Active Ulcerative Colitis", Ital. J. Gastoenterol., 1986; 18: 15-17.|
|19||*||Willoughby, C. et al, 5 Aminosalicyclic Acid (Pentasa) in Enema Form for the Treatment of Active Ulcerative Colitis , Ital. J. Gastoenterol., 1986; 18: 15 17.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5668123 *||Aug 30, 1996||Sep 16, 1997||Synthelabo||Method of maintaining remission from venous ulcers with sulphasalazine and its metabolite|
|US5716648 *||Jun 8, 1994||Feb 10, 1998||Farmaceutisk Laboratorium Ferring A/S||Compositions for use in the regulation of subnormal pH values in the intestinal tract and for treatment of bowel diseases|
|US6326364||Feb 8, 1999||Dec 4, 2001||Cedars-Sinai Medical Center||Use of 5-aminosalicylates as antimicrobial agents|
|US6583128||Aug 29, 2001||Jun 24, 2003||Nobex Corporation||Immunoregulatory compounds and derivatives and methods of treating diseases therewith|
|US6903082||May 23, 2003||Jun 7, 2005||Nobex Corporation||Methods of treating inflammatory conditions of the gastrointestinal tract using 4-APAA and compositions thereof|
|US7425578||Sep 7, 2006||Sep 16, 2008||Biocon Limited||Immunoregulatory compounds and derivatives and methods of treating diseases therewith|
|US7645801||May 16, 2007||Jan 12, 2010||Alaven Pharmaceutical Llc||Reduced irritant enema for treatment of inflammatory bowel disease (IBD)|
|US7932366||Jul 7, 2005||Apr 26, 2011||Biocon Limited||Synthesis of azo bonded immunoregulatory compounds|
|US8048924||Mar 22, 2005||Nov 1, 2011||Biocon Limited||Methods and compositions employing 4-aminophenylacetic acid compounds|
|US8147445||Jun 14, 2005||Apr 3, 2012||C.B. Fleet Company Inc.||Enema dispenser|
|US8217082||Dec 10, 2009||Jul 10, 2012||Alaven Pharmaceutical, Llc||Reduced irritant enema for the treatment of inflammatory bowel disease (IBD)|
|US8314214||Apr 26, 2011||Nov 20, 2012||Biocon Limited||Synthesis of azo bonded immunoregulatory compounds|
|US8754197||Nov 19, 2012||Jun 17, 2014||Biocon Limited||Synthesis of azo bonded immunoregulatory compounds|
|US8845577||Mar 2, 2012||Sep 30, 2014||C.B. Fleet Company, Inc.||Enema dispenser|
|US9533129||Jul 22, 2014||Jan 3, 2017||C.B. Fleet Company, Inc.||Enema dispenser|
|US20050255170 *||May 13, 2004||Nov 17, 2005||Post Sarah S||Large volume enema|
|US20070004800 *||Sep 7, 2006||Jan 4, 2007||Biocon Limited||Immunoregulatory compounds and derivatives and methods of treating diseases therewith|
|US20070005025 *||Jun 14, 2005||Jan 4, 2007||Cox Charles H||Enema dispenser|
|US20100087537 *||Dec 10, 2009||Apr 8, 2010||Alaven Pharmaceutical Llc||Reduced irritant enema for the treatment of inflammatory bowel disease (ibd)|
|US20110066117 *||Nov 23, 2010||Mar 17, 2011||Post Sarah S||Large volume enema|
|U.S. Classification||206/213.1, 514/166|
|International Classification||B65D81/20, A61K9/00, A61K31/60|
|Cooperative Classification||A61K9/0031, B65D81/2092, A61K31/60, B65D2565/387, Y02W30/806|
|European Classification||B65D81/20F2A, A61K31/60, A61K9/00M6|
|Sep 23, 1994||FPAY||Fee payment|
Year of fee payment: 8
|Nov 12, 1998||FPAY||Fee payment|
Year of fee payment: 12